Loading...
Loading...
Exelixis
EXEL today was notified by the Food and Drug
Administration (the “FDA”) that the Company's new drug application (“NDA”) for
cabozantinib as a treatment for patients with progressive, unresectable,
locally advanced, or metastatic medullary thyroid cancer has been removed from
the agenda for the November 8 and November 9, 2012 meeting of the FDA's
Oncologic Drugs Advisory Committee (“ODAC”). As a result, the Company does not
anticipate a discussion of the NDA by ODAC. The previously announced
Prescription Drug User Fee Act (PDUFA) action date remains November 29, 2012.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in